{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:26:13Z","timestamp":1784075173740,"version":"3.55.0"},"reference-count":85,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T00:00:00Z","timestamp":1665619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Cancer is a leading cause of death. Venous thromboembolism (VTE) is an often-overlooked cause of morbidity and mortality in cancer patients that can be readily prevented and treated. Actions are needed to reduce the morbidity and mortality of patients with cancer-associated thrombosis (CAT). There is a need to increase awareness of the impact of CAT on cancer patients\u2019 morbidity and mortality, on their quality of life and to understand the importance of more effective preventions and treatments of VTE in cancer patients. Moreover, it is of great importance to systematically assess the risk of VTE in regard to patients, cancer and treatment-related factors. Unfortunately, there are unmet clinical needs in the prevention and treatment of cancer-associated VTE. In this review, we discuss an action plan to ensure an increased awareness of and education on the issues that need to be addressed in order to improve the provision of appropriate prevention, early diagnosis and effective and safe treatment of VTE to all cancer patients and, ultimately, to reduce morbidity and mortality.<\/jats:p>","DOI":"10.3390\/life12101594","type":"journal-article","created":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T22:21:11Z","timestamp":1665699671000},"page":"1594","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Multidisciplinary Care for the Prevention and Treatment of Venous Thromboembolism in Patients with Cancer-Associated Thrombosis (CAT): Impact of Educational Interventions on CAT-Related Events and on Patients\u2019 and Clinicians\u2019 Awareness"],"prefix":"10.3390","volume":"12","author":[{"given":"Beniamino","family":"Zalunardo","sequence":"first","affiliation":[{"name":"Angiology Unit, San Giacomo Hospital, Castelfranco Veneto, ULSS 2 Marca Trevigiana, 31015 Treviso, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Panzavolta","sequence":"additional","affiliation":[{"name":"Angiology Unit, San Giacomo Hospital, Castelfranco Veneto, ULSS 2 Marca Trevigiana, 31015 Treviso, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Bigolin","sequence":"additional","affiliation":[{"name":"Angiology Unit, San Giacomo Hospital, Castelfranco Veneto, ULSS 2 Marca Trevigiana, 31015 Treviso, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Vison\u00e0","sequence":"additional","affiliation":[{"name":"Angiology Unit, San Giacomo Hospital, Castelfranco Veneto, ULSS 2 Marca Trevigiana, 31015 Treviso, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: A population-based cohort study","volume":"137","author":"Mulder","year":"2021","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00005792-199909000-00001","article-title":"Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data","volume":"78","author":"Levitan","year":"1999","journal-title":"Medicine"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJM200012213432504","article-title":"Prognosis of Cancers Associated with Venous Thromboembolism","volume":"343","author":"Sorensen","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_6","unstructured":"Monreal, M., Calleja Hernandez, M.A., Easaw, J.C., Elalamy, I., Young, A., Bang Jespersen, L., Balthazar-Christensen, V., Domecq, G., Manzanera, J., and Bachman, M. (2019, August 01). Cancer-Associated Thrombosis (CAT), a Neglected Cause of Cancer Death: Actions Needed to Increase Health Outcomes and Reduce Mortality Report Summarising the Findings of an Expert Steering Group Meeting in Belgium. Available online: https:\/\/ecpc.org\/wp-content\/uploads\/2019\/08\/ECPC-White-Paper-Cancer-Associated-Thrombosis-1.pdf."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Giustozzi, M., Franco, L., Agnelli, G., and Verso, M. (2022). Unmet clinical needs in the prevention and treatment of cancer-associated venous thromboembolism. Trend Cardiovasc Med.","DOI":"10.1016\/j.tcm.2022.02.003"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Canonico, M.E., Santoro, C., Avvedimento, M., Giugliano, G., Mandoli, G.E., Prastaro, M., Franzone, A., Piccolo, R., Ilardi, F., and Carmeli, M. (2022). Venous Thromboembolism and Cancer: A Comprehensive Review from Pathophysiology to Novel Treatment. Biomolecules, 12.","DOI":"10.3390\/biom12020259"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.3324\/haematol.2018.209114","article-title":"The Khorana score for prediction of venous thromboembolism in cancer patients: A systematic review and meta-analysis","volume":"104","author":"Mulder","year":"2019","journal-title":"Haematologica"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1111\/jth.13378","article-title":"Predictors of active cancer thromboembolic outcomes: Validation of the Khorana score among patients with lung cancer","volume":"14","author":"Mansfield","year":"2016","journal-title":"J. Thromb Haemost."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.thromres.2017.06.021","article-title":"Incidence, outcome and risk stratification tools for venous thromboembolism in advanced pancreatic cancer\u2014A retrospective cohort study","volume":"157","author":"Kruger","year":"2017","journal-title":"Thromb. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.thromres.2016.12.013","article-title":"The Khorana score for the prediction of venous thromboembolism in patients with pancreatic cancer","volume":"150","author":"Franke","year":"2017","journal-title":"Thromb. Res."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Frere, C., Crichi, B., Bournet, B., Canivet, C., Abdallah, N.A., Buscail, L., and Farge, D. (2020). Primary Thromboprophylaxis in Ambulatory Pancreatic Cancer Patients Receiving Chemotherapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cancers, 12.","DOI":"10.3390\/cancers12082028"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","article-title":"2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19","volume":"23","author":"Farge","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"838","DOI":"10.3324\/haematol.2019.221424","article-title":"Updated meta-analysis on prevention of venous thromboembolism in ambulatory cancer patients","volume":"105","author":"Becattini","year":"2020","journal-title":"Haematologica"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3324\/haematol.2017.169060","article-title":"Comparison of risk prediction scores for venous thromboembolism in cancer patients: A prospective cohort study","volume":"102","author":"Cesarman","year":"2017","journal-title":"Haematologica"},{"key":"ref_18","unstructured":"(2021, June 03). Linea Guida \u201cLa Profilassi Primaria del TEV Nelle Neoplasie Ematologiche (Linfomi, Mieloma Multiplo, Leucemie Acute)\u201d, 20 Maggio 2021. Available online: https:\/\/snlg.iss.it\/wp-content\/uploads\/2021\/06\/LG-346-SIE_profilassi-primaria-TEV-in-neoplasie-ematologiche.pdf."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American society of hematology 2021 guidelines for management of venous thromboembolism: Prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/S0049-3848(14)50006-0","article-title":"Risk stratification strategies for cancer-associated thrombosis: An update","volume":"133","author":"Khorana","year":"2014","journal-title":"Thromb. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11739-012-0784-y","article-title":"A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: The Protecht score","volume":"7","author":"Verso","year":"2012","journal-title":"Int Emerg Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.6004\/jnccn.2013.0164","article-title":"Venous thromboembolism prevention in cancer outpatients","volume":"11","author":"Khorana","year":"2013","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to Prevent Venous Thromboembolism in Patients with Cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJMe1816060","article-title":"Direct Oral Anticoagulants for Thromboprophylaxis in Ambulatory Patients with Cancer","volume":"380","author":"Agnelli","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_27","unstructured":"(2021, November 24). Linee Guida AIOM Tromboembolismo Venoso Nei Pazienti con Tumori Solidi. Edizione 2021. Available online: https:\/\/snlg.iss.it\/wp-content\/uploads\/2021\/11\/LG_227_TEV_Tumori_Solidi_agg2021.pdf."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0140-6736(13)60592-9","article-title":"Risk of venous thromboembolism associated with peripherally inserted central catheters: A systematic review and meta-analysis","volume":"382","author":"Chopra","year":"2013","journal-title":"Lancet"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"12376","DOI":"10.18632\/oncotarget.24212","article-title":"Risk associated with central catheters for malignant tumor patients: A systematic review and meta-analysis","volume":"9","author":"Lv","year":"2018","journal-title":"Oncotarget"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e868","DOI":"10.1200\/JOP.19.00697","article-title":"Successful Model for Guideline Implementation to Prevent Cancer-Associated Thrombosis: Venous Thromboembolism Prevention in the Ambulatory Cancer Clinic","volume":"16","author":"Holmes","year":"2020","journal-title":"JCO Oncol. Pract."},{"key":"ref_31","first-page":"325","article-title":"\u2018Spot the CLOT\u2019: Awareness of cancer-associated thrombosis in healthcare providers","volume":"32","author":"Bayadinova","year":"2022","journal-title":"Can. Onc. Nurs. J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.9243","article-title":"Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: A randomized clinical trial","volume":"314","author":"Lee","year":"2015","journal-title":"JAMA"},{"key":"ref_34","first-page":"CD006650","article-title":"Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer","volume":"6","author":"Kahale","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/S2352-3026(14)70018-3","article-title":"Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): A pooled subgroup analysis of two randomized controlled trials","volume":"1","author":"Prins","year":"2014","journal-title":"Lancet Haematol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1160\/TH14-11-0977","article-title":"Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer","volume":"114","author":"Schulman","year":"2015","journal-title":"Thromb. Haemost."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1111\/jth.13153","article-title":"Oral apixaban for the treatment of venous thromboembolism in cancer patients: Results from the AMPLIFY Trial","volume":"13","author":"Agnelli","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1378\/chest.14-0402","article-title":"Direct oral anticoagulants in patients with VTE and cancer: A systematic review and meta-analysis","volume":"147","author":"Vedovati","year":"2015","journal-title":"Chest"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1055\/s-0040-1712098","article-title":"Direct oral anticoagulants for the treatment of acute venous thromboembolism associated with cancer: A systematic review and meta-analysis","volume":"120","author":"Giustozzi","year":"2020","journal-title":"Thromb. Haemost."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e379","DOI":"10.1016\/S2352-3026(16)30057-6","article-title":"Edoxaban for venous thromboembolism in patients with cancer: Results from a non-inferiority subgroup analysis of the Hokusai-VTE randomized, double-blind, double-dummy trial","volume":"3","author":"Raskob","year":"2016","journal-title":"Lancet Hematol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: Results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.chest.2021.09.037","article-title":"Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism: A Randomized Trial","volume":"161","author":"Planquette","year":"2022","journal-title":"Chest"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of acute venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jth.14662","article-title":"Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial","volume":"18","author":"McBane","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/rth2.12359","article-title":"Direct oral anticoagulants compared to low-molecular-weight heparin for the treatment of cancer-associated thrombosis: Updated systematic review and meta-analysis of randomized controlled trial","volume":"4","author":"Moik","year":"2020","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.mayocp.2020.10.041","article-title":"Direct Oral Anticoagulants Compared with Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis","volume":"97","author":"Riaz","year":"2022","journal-title":"Mayo Clin. Proc."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","article-title":"Antithrombotic therapy for VTE disease: Second update of the CHEST guideline and expert panel report","volume":"160","author":"Stevens","year":"2021","journal-title":"Chest"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jvsv.2019.10.014","article-title":"In-hospital outcomes of catheter-directed thrombolysis versus anticoagulation in cancer patients with proximal deep venous thrombosis","volume":"8","author":"Brailovsky","year":"2020","journal-title":"J. Vasc. Surg. Venous Lymphat. Disord."},{"key":"ref_50","unstructured":"(2020, November 20). NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease v1.2021\u2014Annual on 20 November 2020. Available online: https:\/\/www.nccn.org\/guidelines\/guidelines-process\/transparency-process-and-recommendations\/GetFileFromFileManager?fileManagerId=12199."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/jth.12923","article-title":"Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: The DALTECAN study","volume":"13","author":"Francis","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.thromres.2017.07.004","article-title":"Tinzaparin in cancer associated thrombosis beyond 6 months: TiCAT study","volume":"157","year":"2017","journal-title":"Thromb. Res."},{"key":"ref_53","unstructured":"(2018, October 02). Study for APIxaban Cancer Associated Thrombosis (API-CAT), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03692065."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/S0049-3848(14)50011-4","article-title":"Thrombocytopenia in cancer patients","volume":"133","author":"Liebman","year":"2014","journal-title":"Thromb Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/rth2.12111","article-title":"Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: A systematic review","volume":"2","author":"Lee","year":"2018","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.1182\/bloodadvances.2021005966","article-title":"Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: A prospective, multicenter cohort study","volume":"5","author":"Carney","year":"2021","journal-title":"Blood Adv."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/jth.14015","article-title":"Management of cancer-associated thrombosis in patients with thrombocytopenia: Guidance from the SSC of the ISTH","volume":"16","author":"Lee","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"ref_58","first-page":"171","article-title":"Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: An expert consensus","volume":"17","author":"Napolitano","year":"2019","journal-title":"Blood Transfus."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1111\/jth.13387","article-title":"A meta-analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation","volume":"14","author":"Zwicker","year":"2016","journal-title":"J. Thromb. Haemost."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e01638","DOI":"10.1002\/brb3.1638","article-title":"Risk of intracranial bleeding in patients with primary brain cancer receiving therapeutic anticoagulation for venous thromboembolism: A meta-analysis","volume":"10","author":"Porfidia","year":"2020","journal-title":"Brain Behav."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/onco.13698","article-title":"Safety of Direct Oral Anticoagulants in Central Nervous System Malignancies","volume":"26","author":"Swartz","year":"2021","journal-title":"Oncologist"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jama.293.6.715","article-title":"Malignancies, prothrombotic mutations, and the risk of venous thrombosis","volume":"293","author":"Blom","year":"2005","journal-title":"JAMA"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1111\/j.1538-7836.2012.04817.x","article-title":"Epidemiology and prevention of catheter-related thrombosis in patients with cancer","volume":"10","author":"Lee","year":"2012","journal-title":"J. Thromb. Haemost."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/jth.12527","article-title":"Catheter-associated deep vein thrombosis of the upper extremity in cancer patients: Guidance from the SSC of the ISTH","volume":"12","author":"Zwicker","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"E9","DOI":"10.1002\/ajh.24588","article-title":"Treatment of central venous catheter-associated deep venous thrombosis in cancer patients with rivaroxaban","volume":"92","author":"Laube","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.thromres.2017.04.003","article-title":"A prospective study of rivaroxaban for central venous catheter associated upper extremity deep vein thrombosis in cancer patients (Catheter 2)","volume":"162","author":"Davies","year":"2018","journal-title":"Thromb. Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1016\/j.clinthera.2017.07.041","article-title":"Rivaroxaban in the treatment of PICC-associated upper extremity venous thrombosis","volume":"39","author":"Fan","year":"2017","journal-title":"Clin. Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s11239-019-01807-y","article-title":"The efficacy and safety of a catheter removal only strategy for the treatment of PICC line thrombosis versus standard of care anticoagulation: A retrospective review","volume":"47","author":"Shatzel","year":"2019","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1182\/blood-2015-03-631119","article-title":"Splanchnic venous thrombosis is a marker of cancer and a prognostic factor for cancer survival","volume":"126","author":"Farkas","year":"2015","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.mayocp.2017.10.007","article-title":"Rivaroxaban and apixaban for initial treatment of acute venous thromboembolism of atypical location","volume":"93","author":"Janczak","year":"2018","journal-title":"Mayo Clin. Proc."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1016\/S0049-3848(14)50028-X","article-title":"Cancer-associated unsuspected pulmonary embolism","volume":"133","author":"Bleker","year":"2014","journal-title":"Thromb. Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1111\/jth.15435","article-title":"Outcomes among patients with cancer and incidental or symptomatic venous thromboembolism: A systematic review and meta-analysis","volume":"19","author":"Caiano","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1200\/JCO.18.01977","article-title":"Treatment and long-term clinical outcomes of incidental pulmonary embolism in patients with cancer: An international prospective cohort study","volume":"37","author":"Kraaijpoel","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1182\/blood.2020005819","article-title":"Direct oral anticoagulants for cancer-associated venous thromboembolism: A systematic review and meta-analysis","volume":"136","author":"Mulder","year":"2020","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41572-022-00336-y","article-title":"Cancer-associated venous thromboembolism","volume":"8","author":"Khorana","year":"2022","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/bjh.18276","article-title":"Unanswered questions in cancer-associated thrombosis","volume":"198","author":"Sanfilippo","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jdmv.2020.04.011","article-title":"Impact of multidisciplinary team meetings on the management of venous thromboembolism. A clinical study of 142 cases","volume":"45","author":"Mauger","year":"2020","journal-title":"JMV-Journal de M\u00e9decine Vasculaire"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s11239-021-02512-5","article-title":"Effectiveness of a multidisciplinary care program for the management of venous thromboembolism in cancer patients: A pilot study","volume":"53","author":"Benzidia","year":"2022","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1055\/a-1742-0465","article-title":"Public Awareness on Cancer-Associated Thrombosis among the Greek Population: First Findings from the ROADMAP-CAT Awareness Study","volume":"6","author":"Souliotis","year":"2022","journal-title":"TH Open"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"100557","DOI":"10.1016\/j.ctarc.2022.100557","article-title":"How well do European patients understand cancer-associated thrombosis? A patient survey","volume":"31","author":"Falanga","year":"2022","journal-title":"Cancer Treat. Res. Commun."},{"key":"ref_82","first-page":"215","article-title":"Patient education program at the forefront of cancer-associated thrombosis care","volume":"46","author":"Sebuhyan","year":"2021","journal-title":"J. MedVasc."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Marin-Barrera, L., Mu\u00f1oz-Martin, A.J., Rios-Herranz, E., Garcia-Escobar, I., Beato, C., Font, C., Oncala-Sibajas, E., Revuelta-Rodriguez, A., Areses, M.C., and Rivas-Jimenez, V. (2020). A case-control analysis of the impact of venous thromboembolic disease on quality of life of patients with cancer: Quality of Life in Cancer (Qca) Study. Cancers, 12.","DOI":"10.3390\/cancers12010075"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/bjhp.12213","article-title":"\u201cPost-thrombotic panic syndrome\u201d: A thematic analysis of the experience of venous thromboembolism","volume":"22","author":"Hunter","year":"2016","journal-title":"Br. J. Health Psychol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Font, C., Gomez-Mesa, J.-E., L\u00f3pez-N\u00fa\u00f1ez, J.J., Calder\u00f3n, C., Galindo-Coral, S., Wu, C.C., Ma, J., Kroll, M.-H., and Rojas-Hernandez, C.M. (2022). Measurement of Adherence and Health-related Quality of Life during Anticoagulation Therapy in Cancer Associated-Venous Thromboembolism (VTE): A Multicenter Quantitative Study. Research Square.","DOI":"10.21203\/rs.3.rs-1693582\/v1"}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/12\/10\/1594\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:53:05Z","timestamp":1760143985000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/12\/10\/1594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,13]]},"references-count":85,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["life12101594"],"URL":"https:\/\/doi.org\/10.3390\/life12101594","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,13]]}}}